K
Kona Medical
Hypertension Therapy & Hypertension Treatment | Kona Medical
About Kona Medical
Kona Medical, Inc., established in 2009 by Michael Gertner, MD, is a medical technology company focused on developing a non-invasive treatment for resistant hypertension. The company's creation was rooted in combining Dr. Gertner's inventions with the assets of a preceding therapeutic ultrasound company, Therus Corporation. Dr. Gertner, a former general surgeon with a background in mechanical engineering, leveraged his experience to innovate in the medical device sector.
The company is developing the Surround Sound® Hypertension Therapy System, a device aimed at the multi-billion dollar renal denervation market. This market is experiencing significant growth, driven by the increasing prevalence of hypertension worldwide and a demand for minimally invasive treatment options. The Surround Sound system uses externally delivered, high-intensity focused ultrasound to ablate the renal nerves, which play a role in regulating blood pressure. A key differentiator of this technology is its non-invasive nature; it is designed to be performed outside of a catheterization lab, potentially reducing procedural complexity, cost, and risks associated with radiation or contrast media.
Kona Medical's business model centers on the development and eventual commercialization of this proprietary system, targeting patients with drug-resistant hypertension—a significant segment of the hypertensive population. The company has progressed its technology through several rounds of clinical trials outside the United States. Early and mid-stage trials (WAVE I, II, and III) demonstrated promising safety profiles and significant reductions in blood pressure. For instance, combined results from the WAVE I and II studies showed that 81% of patients had a clinically significant drop in systolic blood pressure at six months, with one study protocol reducing therapy time from 13 to just 3 minutes. A larger, sham-controlled trial, WAVE IV, was initiated to further validate these findings across multiple international sites. However, the technology remains investigational and is not yet approved by the U.S. Food and Drug Administration.
To finance its research and development, Kona Medical has successfully raised significant capital from a syndicate of medical technology investors. The company secured a total of $73.7 million over seven funding rounds, including a notable $30 million Series C round in May 2012 and a $10 million Series D in October 2013, which was specifically allocated for market development in China. Key investors include EW Healthcare Partners, Domain Associates, Morningside Group, and Morgenthaler Ventures. While the company showed considerable early promise and attracted substantial investment, it has been classified as a deadpooled company more recently, with its last funding round occurring in September 2015.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2015 | $10M | $40M | Undisclosed | — |
| SERIES DOther financing | Oct 2013 | $10M | $40M | Morningside | — |
Growth signals
Latest recorded traffic for Kona Medical is 130 monthly website visits, up 18.2% over the last three months. Kona Medical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kona Medical in the Bellevue ecosystem
The Kona Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Other known investors1 additional known investor
University of Washington
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kona Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kona Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











